SynthesisBMC cancer2024
Dabrafenib plus trametinib in low-grade versus high-grade gliomas: a systematic review and meta-analysis.
Synthesis in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evidence-based recommendations for adult high-grade glioma therapy: a critical appraisal of clinical practice guidelines.Neurosurgical review · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDabrafenib plus trametinib is a novel targeted therapy for low-grade (LGG) and high-grade (HGG) gliomas. This systematic review and meta-analysis aimed to evaluate the safety and efficacy of dabrafenib plus trametinib in LGG and HGG gliomas.
methodsThe electronic databases of PubMed/Medline, Scopus, Embase, and Web of Science were searched from inception to 5 September 2024. The meta-analyses, sensitivity analysis, publication bias, and meta-regression were performed through the R program.
resultsNine studies with 313 patients were included. Our data demonstrated that dual blockage resulted in a pooled complete response (CR) rate of 10% (95% CI: 5-18%), partial response rate (PR) rate of 39% (95% CI: 32- 46%), stable disease (SD) rate of 36% (95% CI: 26-46%), and progressive disease (PD) rate of 17% (95% CI: 10- 29%). The PR was significantly higher in LGG (P = 0.03), and the PD was substantially lower in LGG (P < 0.01). Our results demonstrated a pooled overall objective response rate (ORR) of 47% (95% CI: 39-55%) without a significant difference in subgroups (P = 0.36). The meta-regression demonstrated that lower age, BRAF V600 mutation, longer dual blockage treatment duration, and history of prior resection were associated with more favorable outcomes in HGGs. Our meta-analysis revealed a pooled discontinuation due to adverse events (AE) rate of 12% (95% CI: 4- 31%).
conclusionDabrafenib plus trametinib is associated with favorable outcomes in gliomas, especially among those with lower age, BRAF V600 mutation, longer dual blockage treatment duration, and history of prior resection. The co-administration of dabrafenib and trametinib was associated with more favorable outcomes among LGGs than HGGs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.